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Introduction {#sec1}
============

Parkinson\'s disease (PD) is the second most common neurodegenerative disorder, characterized by the preferential degeneration of dopamine neurons in the substantia nigra pars compacta (SNpc). Heterozygous mutations in the glucocerebrosidase gene (*GBA*) encoding the lysosomal enzyme GCase represent the strongest common genetic risk factor for PD ([@bib41]) and have also been associated with other related Lewy body disorders ([@bib17]); however, the underlying molecular mechanisms are still poorly understood.

The association of *GBA* with PD first emerged from clinical studies that demonstrated that relatives of patients with Gaucher\'s disease (GD), a lysosomal storage disease caused by homozygous *GBA* mutations, had an increased incidence of PD ([@bib16]). More recent studies exploring the pathogenic role of homozygous *GBA* mutations in GD have highlighted a role of GCase in mitochondria function, α-synuclein aggregation, and autophagic machinery ([@bib31], [@bib38]). GCase pathology in the context of heterozygous *GBA* mutations in PD have been addressed in recent postmortem ([@bib15]) and patient fibroblast ([@bib33]) studies, and recently in a PD patient human neuronal model ([@bib39]). Overall, mutations in *GBA* and in *LRRK2*, also known to play a role in regulating autophagy ([@bib1]), have emphasized the role for the autophagic/lysosomal pathway as central to the pathogenesis of PD ([@bib42]).

Human induced pluripotent stem cells (iPSCs) derived from patients carrying disease-associated alleles retain the genetic background likely to include disease-permissive genetic modifiers and can be differentiated into highly physiological models of specific cell types to study cellular mechanisms of disease ([@bib25]). Within this paradigm, iPSCs can be differentiated into functional midbrain dopamine neurons to provide a powerful tool to study the genetic contribution to PD ([@bib19]). We have previously developed a highly physiological cellular model of differentiated midbrain dopamine neurons that express key dopaminergic markers, exhibit dopamine synthesis, release, and re-uptake, and show autonomous pace-making and spontaneous synaptic activity ([@bib20]).

Here we study the impact of the common *GBA-N370S* mutation on the phenotype of patient-specific dopaminergic neuronal cultures differentiated from iPSC lines derived from patients with PD and identify deficits in protein homeostasis. Our results suggest that the heterozygous *GBA-N370S* mutation leads to a cellular gain of function, shown by misprocessing of misfolded GCase protein in the ER resulting in ER stress upregulation and autophagic/lysosomal dysfunction leading to an enlargement of the lysosomal compartment in individually identified vulnerable dopamine neurons. Together, these deficits lead to increased release of extracellular α-synuclein from GBA-*N370S* PD human iPSC-derived dopamine neuron cultures, which we show is not associated with exosomes. We propose that the combination of these disturbances impairs protein homeostasis in dopamine neurons contributing to their preferential vulnerability in PD. These data highlight the early pathogenic relevance of GCase function in the autophagic/lysosomal pathway in PD, and may explain the higher risk for heterozygous *GBA-N370S* mutation carriers to develop PD.

Results {#sec2}
=======

Generation of Human iPSCs {#sec2.1}
-------------------------

PD patients and controls from the Discovery clinical cohort established by the Oxford Parkinson\'s Disease Centre (OPDC) were screened for the presence of *GBA-N370S* heterozygous mutation ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We then generated and characterized 22 human iPSC clonal lines from fibroblasts obtained from three unrelated PD patients carrying a *GBA-N370S* heterozygous mutation and three healthy control individuals ([Table S1](#mmc1){ref-type="supplementary-material"}). Detailed characterization of all PD lines used in this study is shown in [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}. Characterization of lines from two of the control individuals has been published previously (Control-2, [@bib44]; Control-1, [@bib20]). All iPSC lines displayed embryonic stem cell-like morphology and expressed pluripotency-associated proteins (TRA-1-60, SSEA-4, and Nanog; [Figure S1](#mmc1){ref-type="supplementary-material"}B). Silencing of retroviral transgenes upon establishment of pluripotency was confirmed by qRT-PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}C), and Sendai virus-reprogrammed lines were checked for clearance of the exogenous genes by RT-PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Pluripotency was also assessed using the PluriTest, which is based upon analysis of transcriptome data from iPSCs and human embryonic stem cells and compares gene expression with a large reference set of genome-wide profiles from multiple cell and tissue types ([@bib34]). Accordingly, all lines used were classified as fully reprogrammed and pluripotent ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Genome integrity was confirmed by Illumina SNP arrays ([Figure S2](#mmc1){ref-type="supplementary-material"}) providing detailed resolution of genome integrity compared with traditional karyotyping or M-FISH. The SNP datasets also enabled confirmation that the iPSC lines derived from the expected fibroblast line. The SNP datasets and the Illumina HT12v4 transcriptome array results have been deposited in GEO: [GSE53426](ncbi-geo:GSE53426){#intref0010}.

Characterization of Dopaminergic Neuronal Cultures {#sec2.2}
--------------------------------------------------

In order to study the effect of the heterozygous *GBA-N370S* mutation in the context of PD, iPSCs were differentiated into dopaminergic neuronal cultures ([Figure 1](#fig1){ref-type="fig"}A). A total of ten different iPSC clonal lines from three control individuals and three PD patients carrying a *GBA-N370S* heterozygous mutation were differentiated into dopaminergic neuronal cultures, as described previously ([@bib20]), with minor modifications. Briefly, embryoid bodies prepared from iPSCs were plated in the presence of SMAD signaling inhibitors (Noggin and SB431542) to initiate neuronal induction, together with CHIR99021 (a potent canonical WNT signaling activator), sonic hedgehog (SHH), and FGF8a for midbrain floor plate induction. By day 20, visible neural rosette structures were manually dissected and re-plated for differentiation into dopaminergic neurons with ascorbic acid, cAMP, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor for 15 days. All lines successfully differentiated into dopaminergic neuronal cultures ([Figure 1](#fig1){ref-type="fig"}B). The differentiation efficiency, assessed by β-3 tubulin and TH expression using immunofluorescence, was similar across the genotypes used in the study ([Figure S3](#mmc1){ref-type="supplementary-material"}). RT-PCR analysis demonstrated that differentiated dopaminergic cultures expressed the floor plate markers FOXA2 and LMX1A, in addition to the mature dopaminergic neuron markers EN1 and NURR1, while the level of the pluripotency marker OCT4 was much reduced on differentiation ([Figure 1](#fig1){ref-type="fig"}C). We confirmed the co-expression of TH with the floorplate marker FOXA2, the marker of the A9 dopaminergic neurons susceptible in PD GIRK2, and the post-mitotic midbrain neuronal marker PITX3, further confirming the mature midbrain identity of the differentiated dopaminergic neurons ([Figure 1](#fig1){ref-type="fig"}C). We have previously confirmed the highly mature, functional dopaminergic phenotype in neurons derived from iPSCs using this protocol ([@bib20]). Neurons exhibit the correct pharmacological and physiological characteristics expected of mature dopamine neurons, including expression of a wide range of midbrain markers, dopamine synthesis and uptake, spontaneous slow autonomous Ca^2+^ pace-making activity, and spontaneous synaptic activity at 5--10 Hz, typical of dopamine neurons of the substantia nigra pars compacta ([@bib20]).

*GBA-N370S* Leads to Aberrant GCase Post-translation Modification and Abnormal Lipid Profiles {#sec2.3}
---------------------------------------------------------------------------------------------

Once we had established a human dopaminergic neuronal culture model consistent between different lines from multiple individuals, we next determined the effect of the heterozygous *GBA-N370S* mutation on GCase protein level in the *GBA-N370S* PD lines. In addition to the expected 60 kDa isoform corresponding to mature GCase, we observed an extra isoform of apparently higher molecular weight only in dopaminergic neuronal cultures derived from *GBA-N370S* PD patients, which represented up to 50% of total GCase in these cultures ([Figure 2](#fig2){ref-type="fig"}A). This N370S-specific isoform was sensitive to treatment with EndoH, which yielded a third, lower molecular weight isoform ([Figure 2](#fig2){ref-type="fig"}B). This demonstrates that a proportion of GCase in the *N370S GBA* cell lines had retained high-mannose oligosaccharides, indicating failure to be processed in the Golgi, likely because of retention in the ER. In *GBA-N370S*-derived dopaminergic neuronal cultures, this EndoH-sensitive GCase isoform was significantly more abundant, representing around 20% of total GCase ([Figure 2](#fig2){ref-type="fig"}B). Samples were further treated with PNGase F to remove both high-mannose and complex N-linked glycans, and under these conditions no significant differences were observed in GCase protein levels between N370S mutant and control dopaminergic neuronal cultures ([Figure 2](#fig2){ref-type="fig"}C). Overall, these results indicate that the *GBA-N370S* mutation likely results in retention in the ER as a result of disrupting the structure and/or folding of the protein, without affecting the total amount of GCase.

LIMP2 is a GCase-specific lysosomal receptor ([@bib37]), which has been associated with PD risk ([@bib10]). In dopaminergic neuronal cultures derived from *GBA-N370S* PD patients, we observed increased LIMP2 protein expression compared with controls, although there was inter-individual variation between the *GBA-N370S* PD lines ([Figure 2](#fig2){ref-type="fig"}D). This result supports a role for LIMP2 in trafficking ER-retained mutant GCase from the ER to the lysosome ([@bib37]).

We next quantified the GCase substrate lipids in *GBA-N370S* PD dopaminergic cultures. No GlcCer accumulation was observed in patient cells, as measured by mass spectrometry quantification of individual species normalized to the ceramide precursor ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Notably, the distribution of GlcCer species was markedly different in *GBA-N370S* PD dopaminergic cultures compared with controls, with a 30% reduction for C20:0 GlcCer and a ∼65% increase of C16:0 and C24:0 species ([Figure 2](#fig2){ref-type="fig"}E). Overall, these data indicate that the *GBA-N370S* heterozygous mutation results in abnormal lipid profiles not previously reported.

ER Stress and Autophagic Disturbances in *GBA-N370S* Dopaminergic Neuronal Cultures {#sec2.4}
-----------------------------------------------------------------------------------

Accumulation of misfolded proteins in the ER can overload the cellular capacity for protein re-folding and induce ER stress, leading to activation of the unfolded protein response (UPR) ([@bib22]). Analysis of the two ER-resident chaperones, Bip/GRP78 and calreticulin, revealed significant upregulation in *GBA-N370S* dopaminergic neuronal cultures when compared with control-derived dopaminergic cultures ([Figure 3](#fig3){ref-type="fig"}A). Upregulation of additional UPR mediators, PDI, calnexin, and IRE1alpha, confirmed UPR activation ([Figures 3](#fig3){ref-type="fig"}B--3D), although cleavage of *XBP1* mRNA was not observed ([Figure S4](#mmc1){ref-type="supplementary-material"}B). *XBP1* splicing might not be a crucial transducer in this context as it has been previously detected in the brain in only one-third of *GBA* mutant PD patients ([@bib15]).

Since ER stress can result in autophagic disturbances ([@bib47]) through the accumulation of misfolded proteins ([@bib22]), we examined the autophagosome content in our cultures by quantifying the levels of LC3B-II and LC3 puncta ([@bib26]). LC3B-II, the lipidated form of the autophagosome marker LC3/Atg8, was significantly increased in *GBA-N370S*-derived dopaminergic neuronal cultures reflecting increased levels of autophagosomes ([Figure 4](#fig4){ref-type="fig"}A). This increase in LC3B-II was supported by immunofluorescence analysis that confirmed an increased number of LC3^+^ puncta in dopamine neurons in *GBA-N370S* compared with controls ([Figure 4](#fig4){ref-type="fig"}B). Furthermore, beclin1, a key regulator of autophagy used to study autophagosome formation, was found increased in *GBA-N370S* dopaminergic neuronal cultures from two patients, consistent with an autophagic perturbation ([Figure 4](#fig4){ref-type="fig"}C).

Impaired Lysosomal Degradation in *GBA-N370S* Dopaminergic Neurons {#sec2.5}
------------------------------------------------------------------

Accumulation of autophagosomes can also reflect a defect in lysosomal clearance ([@bib26]). Since the *GBA-N370S* mutation is located in the catalytic domain of GCase ([@bib46]), we determined the impact of the heterozygous *GBA-N370S* mutation on the activity of this lysosomal enzyme. Dopaminergic neuronal cultures from *GBA-N370S* PD patients had significantly reduced GCase activity (∼50% decrease) when compared with control individuals ([Figure 5](#fig5){ref-type="fig"}A). Since reduced GCase activity could impair the overall lysosomal degradation capacity of dopamine neurons, we analyzed the levels of p62/SQSTM1 that reflect autophagic-mediated degradation ([@bib26]). p62 protein levels were increased specifically in *GBA-N370S* dopaminergic neuronal cultures ([Figure 5](#fig5){ref-type="fig"}B), which supports a defect of these cells in the clearance of autophagic vacuoles. To follow up the findings from *GBA-N370S* cultures, we next compared *GBA-N370S* and control dopamine neurons for ultrastructural alterations by electron microscopy (EM), specifically in identified TH-positive neurons. We found an accumulation of electron-dense debris within lysosomal structures in *GBA-N370S* mutant dopaminergic neurons in TH immunogold-labeled cells, ([Figures 5](#fig5){ref-type="fig"}C--5E), which likely represents undegraded cargo found in *GBA-N370S* dopamine neurons.

Enlarged Lysosomal Compartment in *GBA-N370S* Dopaminergic Neurons {#sec2.6}
------------------------------------------------------------------

Following the previous observations suggesting impaired lysosomal degradation, the lysosomal compartment was analyzed in more detail. Dopaminergic neuronal cultures derived from *GBA-N370S* PD patients showed increased expression of the lysosomal markers LAMP1 ([Figure 6](#fig6){ref-type="fig"}A) and LAMP2A ([Figure 6](#fig6){ref-type="fig"}B) when compared with cultures derived from controls. The levels of cathepsin D, a major lysosomal enzyme involved in α-synuclein degradation ([@bib40]) and associated with GCase deficiency ([@bib45]), was also found increased in dopaminergic neuronal cultures from *GBA-N370S* patients ([Figure 6](#fig6){ref-type="fig"}C).

The enlarged lysosomal compartment was confirmed by EM, which demonstrated a ∼2-fold increase in the number of lysosomes in TH immunogold-labeled cells ([Figures 6](#fig6){ref-type="fig"}D and 6E). Furthermore, the area occupied by lysosomal organelles within TH-positive neurons detected by EM was increased by ∼2.5-fold in *GBA-N370S* cells compared with controls ([Figures 6](#fig6){ref-type="fig"}D and 6F), suggesting an enlargement of the lysosomal compartment. EM data also highlighted that the enlargement of the lysosomal compartment was specific to TH-positive dopaminergic neurons, as no differences were found in TH-negative cells ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), emphasizing the importance of studying a disease-relevant cell type. The enlarged lysosomal compartment may reflect impaired lysosomal degradation capacity in dopamine neurons, which was not altered in TH-negative cells. *GBA-N370S* dopaminergic cultures were still capable of responding efficiently to situations of increased autophagic demand, as demonstrated by increased lysosomal numbers under starvation conditions determined by EM analysis ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Treatment with the V-ATPase inhibitor bafilomycin A1 also resulted in increased number of lysosomes in TH-positive neurons, which indicates that the process of lysosomal biogenesis is still inducible in *GBA-N370S* dopaminergic cultures ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

Increased Extracellular α-Synuclein in *GBA-N370S* Dopaminergic Neuronal Cultures {#sec2.7}
---------------------------------------------------------------------------------

Accumulation of α-synuclein is the characteristic pathological marker of PD and can result from defective cellular clearance mechanisms. α-Synuclein is degraded by multiple pathways including autophagy and the autophagy-lysosome pathway ([@bib7]), and α-synuclein levels have been shown to be altered in response to pharmacologically induced autophagic impairments ([@bib27]) and ER stress ([@bib21]). Analysis of the intracellular α-synuclein content in dopaminergic neuronal cultures from *GBA*-*N370S* PD showed no differences when compared with controls ([Figure 7](#fig7){ref-type="fig"}A). However, recent reports have shown that impairments of the autophagic machinery can affect the release of α-synuclein in neuroblastoma cells, rat primary neurons, and mouse fibroblasts ([@bib2], [@bib11], [@bib12], [@bib23], [@bib30]). We therefore investigated if the autophagic/lysosomal disturbances observed in *GBA*-*N370S* dopaminergic neuronal cultures could alter α-synuclein release in our human PD-specific cell model. Analysis by ELISA revealed the presence of α-synuclein in the culture media of differentiated dopaminergic cultures, which increased over time ([Figure 7](#fig7){ref-type="fig"}B). Importantly, the levels of α-synuclein in the media were found to be increased for mature dopaminergic neuronal cultures differentiated from *GBA-N370S* patients when compared with controls ([Figure 7](#fig7){ref-type="fig"}C), suggesting a possible link between the autophagic/lysosomal disturbances we report and the modulation of α-synuclein release.

The secretion of α-synuclein has been associated with exosomes in α-synuclein overexpressing neuroblastoma cells, following an unconventional secretory pathway ([@bib12]). We therefore examined if a similar mechanism could be associated with α-synuclein release in our PD patient model. Exosomes were isolated from dopaminergic neuronal cultures and analyzed by nanoparticle tracking analysis. This analysis did not reveal any significant difference in the nodal size of exosomes between control and *GBA-N370S* cultures ([Figure S6](#mmc1){ref-type="supplementary-material"}). In addition, there was no difference in the concentration of exosomes secreted by control or *GBA-N370S* dopaminergic cultures ([Figure S6](#mmc1){ref-type="supplementary-material"}). Western blot analysis of extracted exosomes confirmed the detection of generic (CD81) and neuron-specific (L1CAM) exosomal markers, and the absence of calnexin, an indicator of apoptotic bodies ([Figure 7](#fig7){ref-type="fig"}D). These data indicate that extracellular α-synuclein is not associated with neuron-derived exosomes. Accordingly, ELISA analysis showed that exosome depletion of conditioned media did not change the α-synuclein levels in the media and it was estimated that exosome-associated α-synuclein constitutes less than about 1.6% of the total extracellular fraction.

To further investigate the mechanisms resulting in α-synuclein release in dopaminergic cultures carrying *GBA-N370S* mutation, cells were treated with either chloroquine (CQ) or with bafilomycin A1, both of which cause impaired lysosomal function by neutralizing lysosomal pH ([@bib24]). Each treatment resulted in a significant increase in released α-synuclein in *GBA-N370S* dopaminergic cultures ([Figure 7](#fig7){ref-type="fig"}E). Both treatments had a bigger impact on patient cells than controls, suggesting a role for lysosomal function in α-synuclein release in *GBA-N370S* dopaminergic cultures. To explore a possible role for the ER/Golgi-dependent classical export pathway in α-synuclein release, cultures were treated with brefeldin A, which blocks the trafficking between ER and Golgi. Brefeldin A treatment resulted in increased release of α-synuclein in all dopaminergic cultures ([Figure 7](#fig7){ref-type="fig"}E), more pronounced in *GBA-N370S* lines, suggesting that the ER/Golgi vesicle-mediated transport is also involved in α-synuclein release. Overall, these data confirm an increased release of α-synuclein in *GBA-N370S* PD dopaminergic neuronal cultures associated with an impairment of the autophagic/lysosome pathway, offering a possible therapeutic target.

Discussion {#sec3}
==========

Using human iPSCs derived from PD patients carrying the heterozygous *GBA-N370S* mutation, we have identified relevant mechanisms by which a heterozygous *GBA* mutation associated with PD may increase cellular susceptibility to disease. Our results highlight an important role of heterozygous mutant GCase in the disruption of protein homeostasis in dopaminergic neurons, ultimately leading to increased α-synuclein release, which may be central for the early pathogenesis of PD. Differentiation of ten independent iPSC lines from three controls and three unrelated *GBA-N370S* PD patients into dopaminergic neurons allowed us to robustly investigate this genetic contribution in an appropriate human model of early PD pathology.

Our data suggest that the heterozygous *GBA-N370S* mutation results in the retention of GCase within the ER in PD iPSC-derived dopaminergic neuronal cultures. We found no evidence of a reduction of GCase protein levels in our multiple lines derived from three unrelated patients, indicating that the protein is not targeted for degradation. We have observed an overall increased expression of LIMP2, a GCase-specific lysosomal receptor, in dopaminergic cultures from *GBA-N370S* patients. Increased LIMP2 expression is likely to be part of a cellular response to *GBA* mutations, as it has been previously shown that LIMP2 overexpression increases transportation of ER-retained GCase toward the lysosomes ([@bib37]).

We observed the upregulation of multiple ER stress markers in *GBA-N370S*-derived dopaminergic neuronal cultures, which likely reflects a dysregulation of the ER homeostatic environment induced by misprocessing of misfolded GCase similar to a postmortem analysis of PD *GBA* patients showing UPR activation ([@bib15]).

We have also identified alterations in the autophagy pathway in our PD model. Levels of autophagosomes were increased in dopamine neurons from *GBA-N370S* lines, and we provide multiple lines of evidence to support an impairment of general autophagic vacuole clearance. In addition, multiple lysosomal markers were upregulated in *GBA-N370S* dopaminergic lines consistent with an impairment of lysosomal degradation capacity. Moreover, an enlargement of the lysosomal compartment was identified, specifically within TH immunogold-identified dopaminergic neurons derived from patient\'s lines, characterized by increased number and size of lysosomal structures. Lysosomal dysfunction is a key pathological event in PD ([@bib8]), and the specificity to dopamine neurons may explain the preferential vulnerability of these neurons.

Altered cellular lipid composition can be associated with ER disturbances ([@bib3]) and autophagic impairments ([@bib28]). Although the mechanisms underlying cellular distribution of GlcCer species in neurons is not well understood, lipid contents are known to differ in membranes undergoing ER-Golgi maturation or fusion within various organelles ([@bib18]). The different GlcCer species distribution observed in our neuronal cultures between control and *GBA-N370S* lines may be due to the different trafficking of GCase. As a result of altered trafficking, the mutant GCase enzyme may hydrolyze a species that might not have been degraded in normal cells, thereby decreasing total amounts of certain lipids (e.g., 30% reduction of C20:0 GlcCer levels in *GBA-N370S* neurons). On the other hand, reduced GCase concentration in particular sub-compartments may promote the accumulation of other species (e.g., ∼65% increase in C16:0 and C24:0 species) in *GBA-N370S* neurons.

It is known that α-synuclein is degraded in part by the autophagic/lysosomal pathway ([@bib7]). We observed no differences for the intracellular α-synuclein levels in dopaminergic cultures derived from three patients carrying the *GBA-N370S* mutation, which is in line with the report of [@bib39]. Although postmortem studies have suggested the possibility of increased intracellular α-synuclein in brains from PD patients carrying GBA mutations, postmortem tissue likely reflects a much more advanced stage of disease pathology ([@bib4], [@bib15]).

Since recent reports have demonstrated that perturbations of the autophagic pathway can affect α-synuclein release in neuroblastoma cells and mouse fibroblasts, we decided to investigate if a similar mechanism operated in our physiological human model of PD. Interestingly, we observed increased levels of α-synuclein released in the culture media from *GBA-N370S* dopaminergic neuronal cultures, which may be a consequence of the autophagic/lysosomal defects in these cells. To further investigate the potential mechanisms by which *GBA-N370S* mutation results in increased α-synuclein release, dopaminergic cultures were treated with the lysosomal function inhibitors CQ or bafilomycin A1. Each treatment increased the levels of released α-synuclein, further suggesting the involvement of the lysosome in the release of α-synuclein in *GBA-N370S* dopaminergic cultures. These results suggest that the autophagic and lysosomal deficits we describe result in increased α-synuclein release in *GBA-N370S* dopaminergic cultures. The lack of significant increase in released α-synuclein in control cultures after induced lysosomal dysfunction suggests a difference in the way the lysosomes handle α-synuclein between PD and control cultures. In addition, although earlier reports showed that α-synuclein release was independent of the ER/Golgi classical export pathway ([@bib12], [@bib23], [@bib29]), recent studies have shown that in some models, including enteric neurons, α-synuclein release is dependent on ER/Golgi exocytosis ([@bib5], [@bib36]). Our results indicate that α-synuclein release is also sensitive to brefeldin A treatment, supporting a role for the ER/Golgi classical pathway in the release of α-synuclein in both *GBA-N370S* and control dopaminergic cultures. Taken together, our data suggest that α-synuclein release can occur via both conventional and unconventional pathways in dopaminergic neuronal cultures from *GBA-N370S* cells.

α-Synuclein release could be an important early event in the pathology of PD whereby uptake of α-synuclein by neighboring neurons could result in impaired cellular proteostasis ([@bib9]). α-Synuclein involvement in this context might be complex since it was also previously shown to cause ER stress, block ER-Golgi trafficking ([@bib6]), induce lysosomal rupture ([@bib14]), decrease lysosomal function ([@bib7]), and inhibit GCase activity ([@bib31]).

Secreted α-synuclein has also been associated with exosomes in the context of neuroblastoma cells overexpressing α-synuclein ([@bib2], [@bib12]). To expand on the observation of increased α-synuclein release in our model, we extracted and analyzed human iPSC-derived neuronal exosomes. We did not find a readily detectable association of α-synuclein with exosomes in our model, which is consistent with our recent proteomic analysis in serum-derived microvesicles from PD patients ([@bib43]).

Heterozygous *GBA-N370S* mutations are the strongest risk factor for PD and have also been associated with related Lewy body disorders, in particular with dementia with Lewy bodies, where they represent an important risk factor ([@bib35]). Dopaminergic neurons of the substantia nigra are lost in both PD and dementia with Lewy bodies, which may occur through the mechanisms of altered protein homeostasis we describe here. Interestingly, although a *GBA* mutation increases the relative risk for PD by 30-fold compared with the general population ([@bib32]), most *GBA* mutation carriers do not develop disease. This suggests that a *GBA* mutation confers strong susceptibility, but that a second hit, likely genetic or environmental, is required to drive pathology. Pharmacological rescue in PD *GBA-N370S* neurons using chemical chaperones such as isofagomine and ambroxol, or treatment with recombinant GCase, will allow further dissection of the mechanisms by which GBA mutations confer susceptibility to PD and may identify promising protective therapies.

Taken together, our findings suggest that in PD, the heterozygous *GBA-N370S* mutation leads to the misprocessing of GCase, ER stress upregulation, and autophagic/lysosomal dysfunction in dopaminergic neurons. We propose that this combination of disturbances impairs protein homeostasis in dopamine neurons, which leads to increased α-synuclein release. Such cellular events in combination may lead to preferential dopamine neuronal vulnerability in PD.

Experimental Procedures {#sec4}
=======================

Participant Recruitment {#sec4.1}
-----------------------

Participants were recruited to this study having given signed informed consent, which included mutation screening and derivation of hiPSC lines from skin biopsies (Ethics Committee: National Health Service, Health Research Authority, NRES Committee South Central, Berkshire, UK, who specifically approved this part of the study (REC 10/H0505/71).

Culture and Reprogramming of Primary Fibroblasts {#sec4.2}
------------------------------------------------

Skin punch biopsies (4 mm in diameter) were obtained from participants and low passage fibroblast cultures established and transduced with reprogramming retroviruses (c-MYC, KLF4, SOX2, OCT3/4, and Nanog). Colonies displaying iPSC morphology were picked on day 28 and passaged on murine embryonic fibroblasts by manual dissection every 5--7 days. Full characterization information from the PD patient lines is given in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. The control iPSC lines have been described fully elsewhere ([@bib20], [@bib44]).

RT-PCR, Immunocytochemistry, and Western Blot Analysis {#sec4.3}
------------------------------------------------------

These procedures were performed using standard methods and details are given in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. Representative western blots for antibodies used are shown [Figure S7](#mmc1){ref-type="supplementary-material"}.

α-Synuclein Measurements {#sec4.4}
------------------------

An in-house ELISA for the accurate quantification of α-synuclein concentration was developed by using two commercially available α-synuclein-specific antibodies: the monoclonal Syn-1 (BD Transductions) as the capture antibody and the polyclonal C-20 (Santa Cruz) as the detection antibody, which was used after its covalent conjugation with horseradish peroxidase ([@bib13]). MesoScale Discovery assays were used following the manufacturer\'s instructions. Further details are given in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Accession Numbers {#app1}
=================

The SNP datasets and the Illumina HT12v4 transcriptome array results have been deposited in Gene Expression Omnibus under accession number GEO: [GSE53426](ncbi-geo:GSE53426){#intref0015}.
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![Generation and Characterization of iPSC-Derived Dopaminergic Neuronal Cultures\
(A) Schematic overview of conditions used for differentiation of iPSCs into dopaminergic neuronal cultures, with bright field representations of cells at several stages of differentiation (scale bar, 50 μm).\
(B) Immunohistochemistry representation of differentiated dopaminergic neuronal cultures at day 35 showing high expression levels for the neuronal marker β-3 tubulin (red), the dopaminergic neuron marker TH (green), and DAPI (blue).\
(C) RT-PCR analysis showed reduced expression of the pluripotency marker OCT4 and increased expression of floor plate markers (FOXA2 and LMX1A) and mature dopaminergic markers (EN1 and NURR1) in differentiated dopaminergic neuronal cultures (DAn) versus undifferentiated (iPS). Immunofluorescence analyses also confirmed the co-expression of TH with FOXA1, GIRK2, and PITX3 (scale bar, 50 μm). Results are representative of at least three independent differentiation experiments performed in triplicate per cell line.\
See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Aberrant GCase Post-translation Modification in Heterozygous *GBA-N370S* PD Dopaminergic Neuronal Cultures\
Representative western blot for differentiated dopaminergic neuronal cultures demonstrates the presence of two isoforms (gray and black arrows) for GCase protein specific for *GBA-N370S* cultures.\
(A) Quantification of GCase isoforms by western blot (as percentage of total GCase) confirms the higher molecular weight isoform (black bars) to be specific to *GBA-N370S* dopaminergic neuronal cultures, representing up to 50% of total GCase levels.\
(B) The GCase top isoform was sensitive to EndoH treatment shifting to a lower size band (blue arrow). Quantification of the EndoH-sensitive band represented as a percentage of total GCase for the respective line. Student\'s t test; ^∗^p \< 0.0001. PD-S\#1 corresponds to a sporadic PD sample run but not analyzed further in this study.\
(C) No change of total GCase expression levels after PNGase F treatment. Representative western blot and quantification of GCase is shown. Student\'s t test; not significant.\
(D) Increased LIMP2 protein levels in heterozygous *GBA-N370S* PD dopaminergic cultures. Student\'s t test; ^∗^p \< 0.005. In each case, data represent the mean ± SEM from performing at least three independent differentiation experiments per line each analyzed in triplicate.\
(E) Analysis of different GlcCer species (C16:0, C18:0, C20:0, C22:0, C23:0, C24:0, C24:1, C24:0) as a percentage of total GlcCer shows a difference in the distribution of GlcCer species in *GBA-N370S* PD dopaminergic cultures compared with controls. Each bar represents the mean ± SEM of independent differentiated lines: three control and three *GBA-N370S* PD done in triplicate (n = 3). Student\'s t test; ^∗∗∗^p \< 0.005; ^∗∗∗∗^p \< 0.0001.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}A.](gr2){#fig2}

![ER Stress Upregulation in Heterozygous *GBA-N370S* Dopaminergic Neuronal Cultures\
(A) Representative western blot and quantification shows increased protein levels of the ER chaperones Bip and calreticulin.\
(B--D) Representative western blot and quantification of expression of further ER stress markers, namely PDI (B), calnexin (C), and IRE1α (D).\
In each case, data represent the mean ± SEM from performing at least three independent differentiation experiments per line each analyzed in triplicate. Student\'s t test; ^∗^p \< 0.0001. PD-S\#1 corresponds to a sporadic PD sample run but not analyzed further in this study.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}B.](gr3){#fig3}

![Autophagic Disturbances in Heterozygous *GBA-N370S* PD Dopaminergic Neuronal Cultures\
(A) Representative western blot analysis and quantification showing increased LC3B-II protein levels. Student\'s t test; ^∗^p \< 0.0001.\
(B) Increased number of LC3^+^ puncta in TH^+^ cells. Immunofluorescence staining for LC3B (green) in dopaminergic TH-positive neurons (red) in control and PD patient dopaminergic neuronal cultures (scale bar, 20 μm). Student\'s t test; ^∗^p \< 0.0001.\
(C) Representative western blot and quantification of Beclin1 protein levels in differentiated dopaminergic cultures. Student\'s t test; ^∗^p \< 0.05. In each case, data represent the mean ± SEM from performing at least three independent differentiation experiments per line each analyzed in triplicate.](gr4){#fig4}

![Impaired Lysosomal Degradation Capacity in Heterozygous *GBA-N370S* PD Dopamine Neurons\
(A) GCase enzyme activity in differentiated dopaminergic neuronal cultures was reduced to 50% when compared with controls. Student's t test; ^∗^p \< 0.0001.\
(B) Increased p62 protein levels in heterozygous *GBA-N370S* dopaminergic cultures when compared with controls. Representative western blot analysis and respective quantification. In each case, data represent the mean ± SEM from performing at least three independent differentiation experiments per line each analyzed in triplicate. Student\'s t test; ^∗^p \< 0.0001.\
(C) Electron micrographs showing representative examples of undegraded cargo observed within lysosomal structures in TH immunogold-positive *GBA-N370S*-derived neurons. Arrows indicate LAMP1 positive structures of the lysosomal pathway; arrowheads indicate TH immunogold (5 nm). Scale bar, 200 nm.\
(D) Quantification shows increased number of lysosomes with undegraded cargo per TH^+^ cell in *GBA-N370S* cultures compared with controls. Data represent the mean ± SEM of n = 20 cells per line from two independent differentiation experiments. Student\'s t test; ^∗^p \< 0.001.\
(E) A high magnification image reveals double-membrane vesicles corresponding to autophagolysosomes, with arrows indicating double membranes.](gr5){#fig5}

![Enlargement of the Lysosomal Compartment in Dopamine Neurons Derived from PD Patients Carrying a Heterozygous *GBA-N370S* Mutation\
(A--C) Increased protein levels of multiple lysosomal markers in heterozygous *GBA-N370S* PD dopaminergic cultures. Representative western blots and quantifications for the expression of: (A) LAMP1, (B) LAMP2A, and (C) cathepsin D. In each case, data represent the mean ± SEM from performing at least three independent differentiation experiments per line each analyzed in triplicate. Student\'s t test; ^∗^p \< 0.001.\
(D) Electron micrographs showing representative images of immunogold-labeled TH-positive neurons for differentiated controls and *GBA-N370S* neurons in basal and under starvation conditions. Arrows indicate LAMP1-positive structures of the lysosomal pathway. Scale bar, 200 nm.\
(E) Quantification of EM data shows an increase number of lysosomes in basal conditions for TH neurons in *GBA-N370S* cultures compared with controls.\
(F) The lysosomal compartment, represented as a percentage of the cell area occupied by LAMP1-labeled organelles, was also increased in size in TH-positive neurons in basal conditions in *GBA*-*N370S* cultures. In each case, data represent the mean ± SEM of n = 20 cells per line from two independent differentiation experiments. Student\'s t test; ^∗^p \< 0.001.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![Increased Extracellular α-Synuclein in Heterozygous *GBA-N370S*-Derived Dopaminergic Neuronal Cultures\
(A) There is no difference in the intracellular α-synuclein content in dopaminergic neuronal cultures from controls and *GBA-N370S* PD lines. Representative western blot and quantification for intracellular α-synuclein levels.\
(B) Analysis of culture media by ELISA revealed the presence of α-synuclein, which increased over time.\
(C) Levels of extracellular α-synuclein in culture media were higher for heterozygous *GBA-N370S* dopaminergic cultures when compared with controls, during maturation, measured by ELISA. Fold change of neurons at day 31--36 compared with early neurons at day 21. In each case, data represent the mean ± SEM from performing at least three independent differentiation experiments per line each analyzed in triplicate. Student\'s t test; ^∗^p \< 0.001.\
(D) Western blot analysis of culture media extracted exosomes confirmed the expression of CD81 and L1CAM exosomal markers in the absence of calnexin. Data represent the mean of replicates ± SEM from performing at least three independent differentiation experiments per line.\
(E) Modulation of α-synuclein release in differentiated dopaminergic neurons from control and *GBA-N370S* dopaminergic cultures by treatment with CQ, bafilomycin A1, and brefeldin A, measured by the MesoScale Discovery platform. Each bar represents the mean ± SEM of differentiated lines from at least three independent individuals done in duplicate (n = 6--8). Two-way ANOVA; ^∗^p \< 0.05; ^∗∗∗^p \< 0.005; ^∗∗∗∗^p \< 0.0001.\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
